AnabolicMinds Members and IBE Customers,
There has been a lot of controversy regarding Formex recently and where the MCPE group is located on the molecule. The original nomenclature was correct and since both formestane and 4-OH test differ only in the 17 position being an alcohol or ketone, putting the group here makes it structurally similar to both of these compounds. With that being said IBE has decided to discontinue Formex just in case the laws on derivatives are swayed one way as opposed to another. It is all up to interpretation and the last thing we want is one product causing an issue for the rest. This is not a recall, we just feel that with the recent tension in the PH market and the length of time Formex has already been available that it is best we move on to bigger and better things. The compound has also been increasingly difficult to find and we do not want to add to backorders. We are looking to move to a transdermal formestane considering it is already mass produced.
This is one of the problems with innovation in the supplement market. Not only does innovation cost more money and make things harder to find but it makes it difficult to defend based on the current structure of the DSHEA. I hope you understand and we appreciate your continued business.
-IBE
There has been a lot of controversy regarding Formex recently and where the MCPE group is located on the molecule. The original nomenclature was correct and since both formestane and 4-OH test differ only in the 17 position being an alcohol or ketone, putting the group here makes it structurally similar to both of these compounds. With that being said IBE has decided to discontinue Formex just in case the laws on derivatives are swayed one way as opposed to another. It is all up to interpretation and the last thing we want is one product causing an issue for the rest. This is not a recall, we just feel that with the recent tension in the PH market and the length of time Formex has already been available that it is best we move on to bigger and better things. The compound has also been increasingly difficult to find and we do not want to add to backorders. We are looking to move to a transdermal formestane considering it is already mass produced.
This is one of the problems with innovation in the supplement market. Not only does innovation cost more money and make things harder to find but it makes it difficult to defend based on the current structure of the DSHEA. I hope you understand and we appreciate your continued business.
-IBE